Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research programme at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 3 June 2019. Tebentafusp (IMCgp100) is a novel bispecific biologic T cell receptor therapy with an anti-CD3 immune-redirecting effector function and specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
“At ASCO, we will present clinical and biomarker data from our lead bispecific tebentafusp programme that provide insight into its mechanism of action,” said David Berman, Head of Research and Development at Immunocore. “We believe these data will translate across our ImmTAC platform and provide another step towards identifying which patient populations benefit.”
Poster discussion/poster: Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma (Abstract #9523, Poster #94)
- Highlighting new mechanism of action results for tebentafusp (IMCgp100), this poster will be presented by Mark Middleton, MD, Head, Department of Oncology, University of Oxford, on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
- The poster will also be discussed by Sophie Piperno-Neumann, MD, Department of Medical Oncology, Institut Curie, in the Melanoma/Skin Cancers poster discussion session on Monday 3 June, 4:30-6:00 p.m. CDT in Room E451.
Poster: Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma (Abstract #9530, Poster #101)
- In a retrospective analysis, reporting the potential association of rash with overall survival and temporal association of key cytokines with cytokine mediated adverse events for tebentafusp (IMCgp100), this poster will be presented by Omid Hamid, MD, Chief of Translational Research and Immunotherapy and Director of Melanoma Therapeutics, Angeles Clinic, in the Melanoma/Skin Cancers poster session on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
Analyses presented at the meeting stemmed from a Phase 1 clinical trial assessing the safety and tolerability of tebentafusp (NCT01211262).
About Tebentafusp
Tebentafusp is a novel bispecific biologic T cell redirection therapy with an anti-CD3 immune-redirecting effector function that specifically targets the melanoma associated antigen gp100. It is now in pivotal studies for metastatic uveal melanoma. Tebentafusp has Fast Track Designation and Orphan Drug Designation in the US and Promising Innovative Medicine designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).
About Immunocore
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies that have the potential to transform patients’ lives. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and the lead tebentafusp is being investigated in pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005984/en/
Contact information
Immunocore
Louise Conlon, External Affairs and Brand
Communications Manager
T: +44 (0) 1235 438600
E: info@immunocore.com
Follow
on Twitter: @Immunocore
Syneos Health Communications
(Tebentafusp/IMCgp100)
Stephanie Bukantz
T: +973 477 1814
E:
ImmunocorePR@syneoshealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ExtraHop ® Expands Presence in EMEA to Meet Enterprise Demand for NDR4.11.2025 11:00:00 EET | Press release
ExtraHop®, a leader in modern network detection and response (NDR), today announced its expansion into the Nordics and Benelux markets. This strategic move strengthens the company's European footprint on the heels of a period of significant enterprise growth. Following a strong 2024, in which ExtraHop more than doubled its sales to Global 2000 customers in EMEA, the company is bringing its proven momentum to two of the continent's most dynamic markets housing global enterprise headquarters and a thriving ecosystem of world-class tech innovators. To introduce its industry-leading NDR platform to the Nordics and Benelux regions, ExtraHop is extending its distribution agreement with Ignition Technology, a specialist in SaaS-based cybersecurity. Building upon the partnership’s success in the UK and France, the expansion will address growing demand in northern and western Europe, helping customers stay ahead of emerging threats with complete network visibility and context. “ExtraHop’s conti
STV to Deploy Post-Quantum’s Secure Communications Platform, Forms Strategic Cooperation to Deliver Next-Generation Security4.11.2025 11:00:00 EET | Press release
STV Group a.s. (“STV”), one of the world’s fastest-growing defence innovators, has signed a multi-year licence agreement to use Post-Quantum’s groundbreaking quantum-safe communications platform and signed a Strategic Cooperation Agreement to accelerate deployment across Europe, NATO, and global defence markets. With quantum computing threatening to render traditional encryption obsolete, the move positions STV at the forefront of the cybersecurity revolution - arming governments, defence forces, and enterprises with next-generation resilience against “Harvest Now, Decrypt Later” attacks. By fusing Post-Quantum’s NATO-tested modular platform with its own world-class defence solutions, STV is setting a new global benchmark for secure communications and digital trust. Together, the two companies are delivering the most advanced, future-proof systems to protect sensitive data and mission-critical operations - ensuring that even in the quantum era, allied communications remain impenetrable
KRAFTON Records Quarterly Revenue of KRW 870.6 Billion in Q3 20254.11.2025 09:55:00 EET | Press release
KRAFTON, Inc. today announced its third quarter earnings for 2025 in its investor relations (IR) briefing. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), KRAFTON posted revenue of KRW 870.6 billion in the third quarter of 2025, up by KRW 151.3 billion (+21%) from the same period a year ago. The operating profit was KRW 348.6 billion, up by KRW 24.2 billion (+7.5%) in the same period. As a result, the company achieved record-high cumulative performance in the third quarter of this year with revenue at KRW 2.4069 trillion and operating profit at KRW 1.0519 trillion, marking the first time KRAFTON surpassed KRW 1 trillion of operating profit in the first three quarters. Key Performance Highlights for Q3 2025 KRAFTON saw solid performance across all its business segments, including PC (KRW 353.9 billion), mobile (KRW 488.5 billion), console (KRW 10.2 billion), and others (KRW 18 billion). PC platforms set
Maxion Announces Strategic Actions to Serve Growing Demand for Light Vehicle Aluminum Wheels in South America4.11.2025 00:38:00 EET | Press release
Iochpe-Maxion (B3: MYPK3) through its wheels business, Maxion Wheels, announced the strategic expansion of its light vehicle aluminum wheels business in South America with the redeployment of existing global assets to Brazil, and the acquisition of a 50.1% shareholding in Polimetal, a leading producer of aluminum wheels in Argentina. “Passenger car sales continue to rise across South America, with our wheels business, especially light vehicle aluminum wheels, continuing to gain share in Mercosur,” stated Pieter Klinkers, President and CEO of Iochpe-Maxion. “To address this growing market and corresponding aluminum wheel demand, Maxion Wheels is implementing three strategic initiatives. First is the utilization of our global operations, together with our domestic forces in Brazil, to support the immediate additional demand. Second is the redeployment of existing global assets to our two Brazilian light vehicle aluminum wheel plants in Santo Andre and Limeira. And lastly and most strateg
GigaDevice Highlights Breakthroughs Across AI, Power, and Consumer Applications at Embedded World 20253.11.2025 18:00:00 EET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will present its latest breakthroughs in AI-driven facial and voice recognition, power management, and consumer applications, at this year’s Embedded World North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103394601/en/ This is the second running of EWNA, with the expo taking place in Anaheim, CA, from the 4th of November. GigaDevice’s technology will be on display at Booth #6085 throughout the three-day exhibition. Like its European sister show, the event brings together many of the leading developers and system architects from across the embedded electronics sector. GigaDevice's demonstrations will highlight the performance and versatility of its GD32 MCU family across several demanding applications: Edge AI Recognition Systems: GigaDevice will showcase facial and voice reco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom